May 2021 Updates on ED Clinical Trials

Despite a pandemic, our emergency departments are emerging stronger and finding innovative ways to engage in research. Thank you—this work cannot be done without you. As research activities normalize, we hope to broaden the types of studies we pursue. We welcome feedback and your involvement to ensure high-quality studies that integrate into our clinical workflow.

–Bory Kea, MD, MCR, Director of Clinical Trials

For the interested reader, more details on the below research studies can be found at: http://www.ohsu.edu/cprem

COVID-19 STUDIES
- BinaxNOW
- Covid PreVent Trial
- ACTIV-1 (IM)
- ACTIV-3 (TICO)
- ACTIV-4a (AC-INPT)
- COV-BARRIER
- BLUE CLORAL

ACTIVE STUDIES
- Beckman HF
- PACT
- KCENTRA
- Fentalog (ToxIC)
- ICECAP
- BOOST-3
- CLOTT2
- SWAT
- HydraSense
- CLOVERS
- SAVE-O2

OHSU & ADVENTIST STUDIES
- BinaxNOW
- BD COVID (closed)

**Clinical Evaluation of the BinaxNOW® COVID-19 Antigen (Ag) Card**

Objective: To estimate the clinical sensitivity and specificity of the BinaxNOW® COVID-19 Ag card against the reference method, Abbott RealTime SARS-CoV-2, in patients suspected of COVID-19 infection by any healthcare provider (RN, NP, PA, or MD) using nasal swabs. Staff will collect 2 nasal swabs from each subject. Swabs will be shipped to the Sponsor’s central laboratory for reference testing.

Launched: August 2020 Sites: OHSU & Adventist

*Study coordinators, Nancy & Joy, will check with clinical staff on suspected COVID-19 patients (there is no time limit on symptom duration) between Monday – Friday from 9:00-4:00 PM.*
PI: Bory Kea; Coordinator: Nancy Le

Inclusion: Subject is suspected of COVID-19 infection by a healthcare provider.

Exclusion: Subjects with active nose bleeds or acute facial injuries/trauma, currently enrolled in a study to evaluate an investigational drug, already participated in this study, unable/unwilling to provide informed consent, vulnerable populations (prisoners and pregnant woman).

Status: Enrolling; Enrolled: 206

Contact: Nancy Le, Clinical Research Coordinator: lena@ohsu.edu

**Covid PreVent Trial**

Purpose: Evaluating a single treatment of very low dose thoracic radiation in patients with s/sx of severe COVID, but prior to intubation, to determine whether intubation can be avoided. Can be on other trials, get normal meds.

- PI: Ravi Chandra, Radiation Medicine
- Inclusion: >50 yo, s/sx severe COVID (fever, tachypnea, oxygen requirement), hospitalized and sx for less than 9 days
- Exclusion: Mechanical ventilation, prior RT or intrinsic pulmonary disease, CHF exacerbation within 6 months
- Status: Soon to open
- Contact: Ravi Chandra, chandrav@ohsu.edu

**ACTIV-1 (IM) Immune Modulators for Treating COVID-19**

Evaluate multiple immune modulating investigational agents for moderately - severely ill patients with COVID-19.

Launched: October 15, 2020
Study Duration: September 2021

- PI: Akram Khan, MD; Coordinators: PRISM Research Team
- Inclusion: > 18 yo., COVID + (within 14 days) and ongoing symptoms, expected to require hospitalization for > 72 hours, no co-enrollment
- Exclusion: high ALT/AST, neutropenia, lymphopenia, pregnant/breast-feeding, known allergy to agents, active infections other than COVID-19, severe cirrhosis, heart failure, or organ dysfunction
- Status: ACTIVE, Enrolled: 22
- Contact: Akram Khan, khana@ohsu.edu ; Olivia Krol, krolo@ohsu.edu ; page 11912

**ACTIV-3 (Therapeutics for Inpatients with COVID-19 [TICO])**

A platform designed for testing therapeutic monoclonal antibody agents for adults hospitalized for COVID-19

Launched: August 4, 2020
Study Duration: July 2022

- PI: Akram Khan, MD ; Coordinators: PRISM Research Team
- Inclusion: > 18 yo, COVID + and symptomatic (< 12 days)
- Exclusion: received convalescent plasma, serious condition(s) present at enrollment (i.e. stroke, meningitis, encephalitis, congestive heart failure, DVT or PE)
- Status: ACTIVE, Enrolled: 11
- Contact: Akram Khan, khana@ohsu.edu ; Olivia Krol, krolo@ohsu.edu ; page 11912
**ACTIV-4a (Antithrombotic Strategies in Hospitalized Adults with COVID-19 [AC-INPT])**
Evaluating the effects of combining a P2Y12 inhibitor with anticoagulants for adults hospitalized for moderate to severe COVID-19. This is a continuation of the ACTIV-4 study, which evaluated prophylactic vs. therapeutic anticoagulation in adults hospitalized with COVID-19.

Launched: September 4, 2020  
Study Duration: December 2021

- **PI:** Akram Khan, MD  
  - **Coordinators:** PRISM Research Team  
- **Inclusion:** >18 yo., COVID+ and symptomatic, expected to require hospitalization for >72 hours  
- **Exclusion:** comfort care, ICU level of care (including high flow), ventilated, pregnant, low platelet or hemoglobin counts, contraindication to anticoagulation (i.e. recent stroke, bleeding disorder)  
- **Status:** ACTIVE, Enrolled: 20  
- **Contact:** Akram Khan, khana@ohsu.edu; Olivia Krol, krolo@ohsu.edu

**A Study of Baricitinib (LY3009104) in Participants With COVID-19 (COV-BARRIER)**

Launched: August 3, 2020

- **PI:** Akram Khan, MD  
  - **Coordinators:** PRISM Research Team  
- **Inclusion:** >18 yo, COVID+ (within 72 hours) and presenting with disease progression, requires supplemental oxygen, elevated inflammatory markers  
- **Exclusion:** receiving cytotoxic treatments or IVlg/convalescent plasma, received high dose corticosteroids or OAT3 inhibitors, current TB or active/serious infections  
- **Status:** ACTIVE, Enrolled: 19  
- **Contact:** Akram Khan, khana@ohsu.edu; Olivia Krol, krolo@ohsu.edu

**Biology and Longitudinal Epidemiology of PETAL COVID-19 Observational Study (BLUE CORAL)**
An observational study of patients with COVID-19. The study collects demographic, financial, and biological information through surveys, biospecimens, and post-discharge follow up calls.

Launched: August 2020  
Study Duration: May 2021

- **PI:** Akram Khan, MD  
  - **Coordinators:** PRISM Research Team  
- **Inclusion:** >18 yo., COVID + with fever or respiratory symptoms  
- **Exclusion:** failure to randomize within 72 hours of hospitalization, patients on comfort care, prisoners  
- **Status:** ACTIVE, Enrolled: 126  
- **Contact:** Akram Khan, khana@ohsu.edu; Olivia Krol, krolo@ohsu.edu

**ACTIVE STUDIES**

**Beckman Heart Failure**
The purpose of this study is to collect blood samples for the evaluation of the Access Natriuretic Peptide assay as an aid in the diagnosis of acute HF and assessment of severity of individuals suspected of having HF.
Launched: May 6, 2021

**Enrolling between Monday – Friday from 9:00-4:00 PM.**

- **PI**: Bory Kea, **Coordinator**: Joy Kim
- **Inclusion**: ≥21 years, presenting with a suspicion of acute HF
- **Exclusion**: Dyspnea not secondary to HF (lung disease, trauma, etc.), Stage 4 or 5 CKD, chronic dialysis, participation in a clinical study that may interfere with participation in this study.
- **Status**: Enrolling
- **Contact**: Joy Kim, kimjoy@ohsu.edu

**PACT- Prehospital Airway Control Trial**

PACT is an open-label, multi-site, stepped wedge randomized trial comparing a standard strategy of airway management with a strategy of first attempt with supraglottic airway (SGA) for trauma patients in a prehospital setting. The primary outcome is 24-hour mortality. It is assessed 24 hours after hospital arrival. Eight local agencies in the Clackamas and Washington counties are participating including AMR Clackamas, Clackamas County Fire District 1, Lake Oswego Fire, Molalla Fire, Canby Fire, Tualatin Valley Fire & Rescue, Hillsboro Fire & Rescue, and Metro West Ambulance.

Launched: April 1, 2021

- **PI**: Mo Daya, **Co-I**: Marty Schreiber **Coordinator**: Nancy Le, Nolan Pow, Sam Underwood
- **Inclusion**: Trauma requiring advanced airway management. Indicators of the need for advanced airway management include: a) GCS < 8, b) SpO2 < 90 despite supplemental oxygen, c) ETCO2 > 60 despite supplemental ventilation, or d) provider discretion. **Transport to LITES Trauma Center – OHSU ONLY.**
- **Exclusion**: <15 years of age, pregnant, prisoner, initial advanced airway attempted by a non-PACT agency, in cardiac arrest without ROSC at time of intervention, caustic substance ingestion, airway burns, objection to enrollment voiced by subject or family members at the scene.
- **Status**: Enrolling; Enrolled: 12
- **Contact**: Nancy Le, lena@ohsu.edu

**KCENTRA**

A multicenter, pre-hospital pilot trial to determine the feasibility and safety of Kcentra administration for the early treatment of patients with traumatic shock, compared to placebo, in the field. This study will be conducted under EFIC (Exception from Informed Consent).

Launched: March 2021 **Site s: OHSU and sites at Houston (2) and Seattle (1)**

- **PI**: Schreiber, **Coordinators**: Samantha Underwood and Keeley McConnell
- **Registered with ClinicalTrials.gov**: NCT04019015
- **FDA IND**: Martin Schreiber, 18153
- **Inclusion**: 18 years and older, SBP <70 or no palpable pulse, suspicion of hemorrhagic shock, transport to participating hospital
- **Status**: Active
- **Contact**: Dylan Payton, paytond@ohsu.edu

**Predicting medical consequences of novel fentanyl analog overdose using the Toxicology Investigators Consortium (ToxIC)**

Purpose of this multi-center study is molecular identification and quantitation of fentanyl analogues (fentalogs) in a prospective cohort of 1000 Emergency Department (ED) patients with opioid overdose (OD) from the established ToxIC hospital network. The number of subjects to be enrolled at each ToxIC site is approximately between 25-100. As an Exploratory Sub-Aim, we will characterize psychostimulant drug co-
Ingestions with fentalogs (e.g. synthetic cannabinoids, cocaine, cathinones, etc.) to provide confirmatory identification and quantitation.

**Launched: November 2020**

- **PI:** Adrienne Hughes; **Study Coordinator:** Joy Kim
- **Inclusion:** ED patient Opioid OD. Availability of waste blood or urine specimens for analysis.
- **Exclusion:** Age < 18 years. Non-toxicological diagnosis. Prisoners. Trauma/Bums.
- **Status:** Enrolling; **Enrolled:** 22
- **Contact:** Joy Kim, kimjoy@ohsu.edu

<table>
<thead>
<tr>
<th>ICECAP - Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (a SIREN Network study)</th>
</tr>
</thead>
<tbody>
<tr>
<td>This study will enroll comatose adult survivors of out of hospital cardiac arrest that have already been rapidly cooled using a definitive temperature control method.</td>
</tr>
<tr>
<td><strong>Launched:</strong> September 2020 <strong>Site:</strong> Portland Adventist ED</td>
</tr>
<tr>
<td><strong>ICECAP PI:</strong> Daya, <strong>ICECAP Co-I:</strong> Julia Durrant (OHSU), Miko Enomoto (OHSU), Josh Lupton (OHSU &amp; Portland Adventist), Marwan Mouammar (Portland Adventist), Matthew Neth (Portland Adventist), William Spurlock (Portland Adventist), <strong>Coordinator:</strong> Nancy Le</td>
</tr>
<tr>
<td>- Registered with ClinicalTrials.gov: NCT 04217551</td>
</tr>
<tr>
<td>- FDA IDE: William Meurer, G160072</td>
</tr>
<tr>
<td>- <strong>Status:</strong> Enrolling; <strong>Enrolled:</strong> 17; <strong>All site total:</strong> 209</td>
</tr>
<tr>
<td>- <strong>Contact:</strong> Nancy Le, <a href="mailto:lena@ohsu.edu">lena@ohsu.edu</a></td>
</tr>
<tr>
<td>For more information: <a href="https://siren.network/clinical-trials/icecap">https://siren.network/clinical-trials/icecap</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BOOST-3 Brain Oxygen Optimization in Severe TBI Phase-3 Trial (a SIREN Network study)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BOOST 3 is a trial run through the nationwide SIREN Network. This study is comparing two strategies currently used for monitoring and treating patients with severe traumatic brain injury in the ICU. BOOST 3 allows for EFIC (Exception from Informed Consent) if an LAR is not present (within 6 hours).</td>
</tr>
<tr>
<td><strong>Launched:</strong> March 16, 2020</td>
</tr>
<tr>
<td><strong>BOOST-3 PI:</strong> David Zonies, <strong>SIREN PI:</strong> Daya, <strong>Coordinators:</strong> Keeley McConnell (TRG), Jenny Cook EM Coordinator</td>
</tr>
<tr>
<td>- Registered with ClinicalTrials.gov: NCT03754114</td>
</tr>
<tr>
<td>- <strong>Status:</strong> Enrolling; <strong>Enrolled:</strong> OHSU: 13; <strong>All site total:</strong> 153</td>
</tr>
<tr>
<td>- Study has received approval to continue during Research Level 2 operations</td>
</tr>
<tr>
<td>- <strong>Contact:</strong> Keeley McConnell, <a href="mailto:mcconnke@ohsu.edu">mcconnke@ohsu.edu</a></td>
</tr>
<tr>
<td>For more information: <a href="https://www.ohsu.edu/school-of-medicine/emergency/boost-3-study">https://www.ohsu.edu/school-of-medicine/emergency/boost-3-study</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CLOTT2 - The Pathogenesis of Post traumatic Pulmonary Embolism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigation into the significance of incidentally discovered venous thromboembolism following trauma and the role of fibrinogen break down in the development of post-traumatic VTE.</td>
</tr>
<tr>
<td><strong>Launched:</strong> May 2018</td>
</tr>
<tr>
<td><strong>PI:</strong> Kiraly, Laszlo; <strong>Coordinator:</strong> Dylan Payton</td>
</tr>
</tbody>
</table>
- **Inclusion**: >18 yo and ≥ 40 yo with ICU admission expected for ≥ 3 days and has at least one risk factor
- **Exclusion**: Outside of age range, direct admit to ward, and/or minor injuries
- **Status**: Enrolling
- **Contact**: Dylan Payton, paytond@ohsu.edu

### SWAT - Shock, Whole blood and assessment of TBI
Evaluate outcomes associated with early whole blood resuscitation practice as compared to component resuscitation in poly trauma patients with hemorrhagic shock and further characterize outcome benefits in those with TBI.

**Launched**: November 2018

- **PI**: Schreiber, Martin; **Coordinator**: Sean Van Walchren
- **Inclusion**: blunt or penetrating trauma who meet 2 or more of the following criteria (SBP < 90mmhg, penetrating mechanism, + FAST and/or Tachycardia); and receives at least 1 unit of blood and goes to the OR within 60 minutes of arrival.
- **Exclusion**: <15, CPR > 5 consecutive minutes without ROSC, penetrating TBI with brain matter exposed, ED death, know pregnancy and/or prisoner
- **Status**: Enrolling; **Enrolled**: 83; All site total: 810
- **Contact**: Sean Van Walchren, vanwalch@ohsu.edu

### Digital Capillary Refill with HydraSense
Using a novel device (HydraSense) to compare manual vs digital capillary refill: currently enrolling in patients 6mo-65yo.

This study requires NO work or input from RNs or MDs. The study team will work around staff with any patients they enroll to make sure and prioritize your time with them over the study.

**Launched**: September 12, 2018

- **PI**: Sheridan; **Coordinator**: Nancy Le
- **Status**: Enrolling; **Enrolled**: 351; Enrollment Goal: 600
- **Contact**: Nancy Le, lena@ohsu.edu

### HydraSense for Sepsis

**Launched**: June 24, 2019

- **PI**: Sheridan; **Coordinator**: Tyne Riddick
- **Status**: Enrolling; **Enrolled**: 170 total, 15 sepsis enrollments
- **Contact**: Tyne Riddick; riddick@ohsu.edu

### CLOVERS (Fluids vs. Vasopressors)
Evaluating if a liberal or restrictive fluid strategy is the more appropriate initial approach in patients with suspected infection and low blood pressure.
Launched: March 7, 2018
Study Duration: June 2021

- PI: Akram Khan, MD (khana@ohsu.edu); Coordinators: PRISM Research Team
- Inclusion: > 18 yo, suspected/confirmed infection (planned antibiotics), sepsis (systolic < 100 mmHg or MAP < 65 mmHg) or use of vasopressors after receiving 1 L of IV fluids
- Exclusion: Not able to be enrolled within of 4 hrs of meeting inclusion and within 24 hrs of presentation, received > 3 L of fluids, pregnant, hypotension at baseline, pulmonary edema, severe volume depletion NOT due to sepsis
- Status: ACTIVE, Enrolled: 179
- Contact: Akram Khan, khana@ohsu.edu; Olivia Krol, krolo@ohsu.edu; page 11912

SAVE-O2 - Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients
SAVE-O2 will be a multicenter cluster randomized, stepped wedge implementation trial of a multimodal educational intervention to target normoxia in adult trauma patients admitted to the intensive care unit (ICU). The goal is to improve oxygenation to >90% of eligible patient-hours spent in the desired normoxia range, excluding time without supplemental oxygen or time on FiO2 100% and below the normoxia range.

Launched: October 15, 2020

- PI: Schreiber, Coordinator: Samantha Underwood
- Inclusion: Patients who meet criteria for entry into the OHSU trauma registry
- Exclusion: Age <18 years, Prisoners, Known pregnancy, Transferred patients not admitted through the emergency department
- Status: Active
- Contact: Samantha Underwood, underwos@ohsu.edu

CLOSED STUDIES

C3PO- Clinical Trial of COVID-19 Convalescent Plasma of Outpatients – a SIREN Network Trial
The Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) is a multi-center randomized, single-blind, two-arm, placebo-controlled phase III trial with blinded outcome assessment to establish the safety and efficacy of a single dose of convalescent plasma (CP) for preventing the progression from mild to severe COVID-19 illness. This trial will be conducted in the OHSU Emergency Department.

Launched: August 19, 2020

- PI: Bory Kea; Coordinator: Jenny Cook
- Status: Closed; Enrolled: 27; All sites: 511
- Registered with ClinicalTrials.gov: NCT04355767
BD COVID-19
A prospective, multi-center study with the purpose of collecting nasal swabs from people diagnosed or suspected of having COVID-19 to use in the future to help make new tests for detecting this virus and/or make current tests better.

Launched: March 2021 Site: Portland Adventist ED

- **PI:** Bory Kea, **Coordinator:** Nancy Le
- **Inclusion:** ≥18 years, presenting with COVID-19 symptoms: fever, dry cough, SOB, muscle pain, headache, sore throat, extreme tiredness, diarrhea, runny or stuffy nose, and new loss of taste or smell.
- **Exclusion:** Unable to collect all study swabs at time of collection
- **Status:** Closed 4/14/21; **Enrolled:** 11

Solace
Wearable technology for physiologic monitoring of adolescent suicidality: enrolls adolescents presenting with suicidality with goal of developing objective/physiologic markers that correlate with escalating suicidality.

Launched: September 25, 2017

- **PI:** Sheridan; **Coordinator:** Nancy Le
- **Status:** Closed; **Enrolled:** 181